Neovacs SA - Product Pipeline Review - 2015

Date: December 30, 2015
Pages: 29
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N34DD3C86ACEN
Leaflet:

Download PDF Leaflet

Neovacs SA - Product Pipeline Review - 2015

SUMMARY

Global Markets Direct’s, ‘Neovacs SA - Product Pipeline Review - 2015’, provides an overview of the Neovacs SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neovacs SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides brief overview of Neovacs SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neovacs SA’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neovacs SA’s pipeline products
REASONS TO BUY
  • Evaluate Neovacs SA’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neovacs SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neovacs SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neovacs SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neovacs SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neovacs SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Neovacs SA Snapshot
Neovacs SA Overview
Key Information
Key Facts
Neovacs SA - Research and Development Overview
Key Therapeutic Areas
Neovacs SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Neovacs SA - Pipeline Products Glance
Neovacs SA - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Neovacs SA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Neovacs SA - Drug Profiles
Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target TNF Alpha for Crohn's Disease, Rheumatoid Arthritis and Psoriasis
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target VEGF-Alpha for Age Related Macular Degeneration and Solid Tumors
Product Description
Mechanism of Action
R&D Progress
Neovacs SA - Pipeline Analysis
Neovacs SA - Pipeline Products by Target
Neovacs SA - Pipeline Products by Route of Administration
Neovacs SA - Pipeline Products by Molecule Type
Neovacs SA - Recent Pipeline Updates
Neovacs SA - Dormant Projects
Neovacs SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neovacs SA, Key Information
Neovacs SA, Key Facts
Neovacs SA - Pipeline by Indication, 2015
Neovacs SA - Pipeline by Stage of Development, 2015
Neovacs SA - Monotherapy Products in Pipeline, 2015
Neovacs SA - Phase II, 2015
Neovacs SA - Preclinical, 2015
Neovacs SA - Pipeline by Target, 2015
Neovacs SA - Pipeline by Route of Administration, 2015
Neovacs SA - Pipeline by Molecule Type, 2015
Neovacs SA - Recent Pipeline Updates, 2015
Neovacs SA - Dormant Developmental Projects,2015
Neovacs SA, Subsidiaries

LIST OF FIGURES

Neovacs SA - Pipeline by Top 10 Indication, 2015
Neovacs SA - Pipeline by Stage of Development, 2015
Neovacs SA - Monotherapy Products in Pipeline, 2015
Neovacs SA - Pipeline by Top 10 Target, 2015
Neovacs SA - Pipeline by Top 10 Route of Administration, 2015
Neovacs SA - Pipeline by Top 10 Molecule Type, 2015
Skip to top


Mild Psoriasis - Pipeline Review, H1 2015 US$ 1,600.00 Apr, 2015 · 48 pages
Pyelonephritis - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 48 pages
Lipotek Pty Ltd. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 20 pages
Hypercholesterolemia - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 243 pages

Ask Your Question

Neovacs SA - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: